Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
No Scars is a topical dermatological combination cream developed and marketed by Torque Pharmaceuticals. It is formulated with three active ingredients: hydroquinone (2% w/w), tretinoin (0.025% w/w), and mometasone furoate (0.1% w/w). Hydroquinone acts as a skin-lightening agent by inhibiting the enzyme tyrosinase, which is essential for melanin production. Tretinoin, a retinoid, promotes epidermal cell turnover and collagen production, helping to unclog pores and improve skin texture. Mometasone furoate is a medium-potency corticosteroid that reduces inflammation and suppresses melanocyte metabolism. The product is indicated for the short-term, intermittent treatment of moderate to severe melasma, dark spots, acne scars, and other forms of hyperpigmentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on No Scars.